MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Johnson & Johnson, Inc. [J&J] (NYSE:JNJ)*
Organization & Developments: Johnson & Johnson (J&J)
Parents
Johnson & Johnson, Inc. [J&J] (NYSE:JNJ)*
Children
@JNJNews
*Asia Pacific Innovation Center located in Suzhou, China
*Depuy Ireland
*Developments: Johnson & Johnson (Archives 2010 -2015)
*Developments: Johnson & Johnson (Archives 2016 -2017)
*Developments: Johnson & Johnson (Archives 2018 -2020)
*Developments: Johnson & Johnson (J&J)
*DexCom has joint development agreements with insulin pump manufacturers Animas Corporation, a subsidiary of Johnson & Johnson, a
*Discharge Decision Support System (D2S2)
*Ethicon division provides surgical systems and instruments.
*Innovation Centers
*Its interventional solutions business provides tools for heart rhythm disorders and neurovascular care.
*J&J Healthcare Systems Major Pharmaceuticals
*Johnson & Johnson (JNJ) division DePuy Synthes houses its orthopedics division (joint reconstruction, spine, sports medicine, and cranio-maxillofacial devices)
*Johnson & Johnson: Consumer & Personal Products
*Johnson & Johnson: Organizations & Brands
*Johnson& Johnson: Business Essentials
*New Brunswick, New Jersey 08901
*Organization: Johnson & Johnson (J&J)
*SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2 CORONARY INTRAVASCULAR LITHOTRIPSY (IVL) CATHETER
*Stelara (ustekinumab)
*Verb Surgical
2019: J&J takes over Verb Surgical as Verily exits robotics partnership
2021: J&J Reports Vaccine Results
2021: J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division
2022: J&J debuts Kenvue as new name for $15B consumer health business spinoff
2022: J&J's Ethicon, CMR Surgical pair up on minimally invasive robotic surgery
2022: J&J's Heart Deal Pumps Up Post-Breakup Prospects_ seekingalpha.com
2022: Johnson & Johnson Goes Back Into Cardiology With A Big Splash_ seekingalpha.com
2022: Johnson & Johnson taps Scottish inspiration in branding its consumer spinoff
2022: Johnson & Johnson: Aspects To Consider After Acquiring Abiomed_ seekingalpha.com
2022: Johnson & Johnson: Steady Growth Play_ seekingalpha
2022: Outlooks Continue To Favor Johnson & Johnson_seekingalpha.com
2023: ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma, with one med showing 'unprecedented' efficacy
2023: Johnson & Johnson MedTech: ‘Stay tuned’ for Ottava next-gen surgical robot
2023: Johnson & Johnson Stock (NYSE:JNJ): Time to Buy the Dip?_www.tipranks.com
2023: Johnson & Johnson: An Update Following The Kenvue IPO_ seekingalpha.com
2023: Johnson & Johnson: Q3 Earnings Unveils Life After Kenvue Spinoff
2023: Johnson & Johnson: Starting To Look Interesting Again_seekingalpha.com
2023: Johnson & Johnson: The Bull Case Can No Longer Be Ignored
2024: 4 Positives For Johnson & Johnson
2024: 6 ways Johnson & Johnson is using AI to help advance healthcare
2024: As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan
2024: Decoding Johnson & Johnson (JNJ): A Strategic SWOT ..
2024: DLA_Johnson & Johnson Health Care Systems Inc., awarded a maximum $86,115,042 fixed-price, indefinite-delivery/indefinite-quantity contract for joint orthopedic procedural packages and supplies.
2024: Growth Prospects Enhanced by Key Acquisitions and Approvals
2024: Is Johnson & Johnson (NYSE:JNJ) a Worthwhile Dividend Stock? _ www.tipranks.com
2024: J&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s Candidates
2024: J&J’s Ottava surgical robot to begin clinical trial after FDA nod
2024: Johnson & Johnson 2023 Q4 - Results - Earnings Call Presentation
2024: Johnson & Johnson 2024: Above-market growth continues
2024: Johnson & Johnson Announces Collaborative Effort with USAID to Strengthen the Health Workforce Across Latin America and the Caribbean
2024: Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
2024: Johnson & Johnson revenue 2005-2023
2024: Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business_ seekingalpha.com
2024: Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds
2024: Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
2024: Johnson & Johnson: Buy This Bargain Before It's Gone
2024: Johnson & Johnson: Dividend Legend At A Discount
2024: Johnson & Johnson: One Of The World's Safest Stocks Could Return +10% Per Year_ seekingalpha.com
2024: Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensiveseekingalpha.com
2024: Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments
2024: Johnson & Johnson: Remaining A Buy Despite Remaining Risks
2024: Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook
2024: Johnson & Johnson: The Dividend King Is Back
2024: Johnson & Johnson: Tracking Well Above The Industry
2024: Johnson & Johnson: Wait For More Clarity (Rating Downgrade)
2024: Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
2024: Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
2024: Johnson & Johnson's Acquisition Of Ambrx Biopharma: Hold Through It_ seekingalpha.com
2024: Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook_ seekingalpha.com
2024: Johnson & Johnson’s new robotic surgical system to rival Intuitive Surgical’s da Vinci
2024: Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
2024: With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners
2025: #10. Stelara (ustekinumab) Janssen Biotech (Johnson & Johnson) 2024 Sales: $10.361 billion 2023 Sales: $10.858 billion % Change: -4.6%
2025: #8. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Johnson & Johnson and Genmab3 2024 Sales: $11.670 billion3 2023 Sales: $9.744 billion3 % Change: +19.8%
2025: Advice from J&J MedTech’s global digital head on understanding user needs, building trust in AI, digitization efforts and more
2025: FDA approves Darzalex as 1st drug for smoldering multiple myeloma
2025: J&J MedTech Advances Surgical Innovation With NVIDIA Physical AI
2025: J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients
2025: Johnson & Johnson Could Serve As High-Yield Bond Alternative
2025: Johnson & Johnson MedTech advances robotics with Nvidia AI
2025: Johnson & Johnson SWOT Analysis (2025)
2025: Johnson & Johnson to separate DePuy Synthes ortho business
2025: Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued
2025: Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth
2025: Johnson & Johnson: Rich History Of Excellence Poised To Endure_seekingalpha.com
2025: Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
2025: Ronovo Surgical raises $67M for surgical robot, inks J&J collab
2025: SWOT Analysis of Johnson & Johnson (Updated 2025)
2025: The biggest orthopedic device stories out of AAOS 2025
2025: What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies
2025: What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies
2025: Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
2026: #5 Icotrokinra, Company: J&J/Protagonist Used for: Autoimmune conditions Est. 2032 sales: $2.2 billion
2026: J&J multiple myeloma drug Talvey cuts mortality risk (JNJ:NYSE) | Seeking Alpha
2026: J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial
2026: Johnson & Johnson wins FDA nod for Ottava surgical robot
Johnson & Johnson Development Corporation (JJDC)
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JLABS (JLABS)
Johnson & Johnson:Driving Forces
Jumps
**Key People: Johnson & Johnson (J&J)
Finance & Acquisition: Johnson & Johnson (J&J)